



Engel et al. Cardiovascular Diabetology 2013, 12:3
http://www.cardiab.com/content/12/1/3ORIGINAL INVESTIGATION Open AccessCardiovascular safety of sitagliptin in patients
with type 2 diabetes mellitus: a pooled analysis
Samuel S Engel*, Gregory T Golm, Deborah Shapiro, Michael J Davies, Keith D Kaufman and Barry J GoldsteinAbstract
Objective: To compare the incidence of cardiovascular events and mortality in patients with type 2 diabetes
mellitus treated with sitagliptin or non-sitagliptin comparators.
Methods: A post hoc assessment of cardiovascular safety in 14,611 patients was performed by pooling data from
25 double-blind studies, which randomised patients at baseline to sitagliptin 100 mg/day or a non-sitagliptin
comparator (i.e., non-exposed). Included studies were limited to those at least 12 weeks in duration (range: 12 to
104 weeks). Patient-level data were used in this analysis of major adverse cardiovascular events (MACE) including
ischaemic events and cardiovascular deaths. Analyses were performed in three cohorts: the entire 25-study cohort,
the cohort from placebo-controlled portions of studies (n=19), and the cohort from studies comparing sitagliptin to
a sulphonylurea (n=3).
Results: In the entire cohort analysis, 78 patients had at least 1 reported MACE-related event, with 40 in the
sitagliptin group and 38 in the non-exposed group. The exposure-adjusted incidence rate was 0.65 per 100
patient-years in the sitagliptin group and 0.74 in the non-exposed group (incidence rate ratio = 0.83 [95%
confidence interval (CI): 0.53, 1.30]). In the analysis comparing sitagliptin to placebo, the exposure-adjusted
incidence rate was 0.80 per 100-patient-years with sitagliptin and 0.76 with placebo (incidence rate ratio = 1.01
[95% CI: 0.55, 1.86]). In the analysis comparing sitagliptin to sulphonylurea, the exposure-adjusted incidence rate
was 0.00 per 100 patient-years with sitagliptin and 0.86 with sulphonylurea (incidence rate ratio = 0.00 [95%
CI: 0.00, 0.31]).
Conclusion: A pooled analysis of 25 randomised clinical trials does not indicate that treatment with sitagliptin
increases cardiovascular risk in patients with type 2 diabetes mellitus. In a subanalysis, a higher rate of
cardiovascular-related events was associated with sulphonylurea relative to sitagliptin.Introduction
Type 2 diabetes mellitus is associated with an increased risk
of cardiovascular disease and mortality [1,2]. Cardiovascular
events account for approximately 70% of deaths in older
patients with type 2 diabetes mellitus [3]. Furthermore,
short- and long-term survival following a myocardial infarc-
tion is lower in patients with type 2 diabetes mellitus com-
pared to those without [4-8]. In a prospective observational
study, the risk of a subsequent myocardial infarction in
patients with pre-existing diabetes was found to be compar-
able to patients with pre-existing coronary disease [9].
These and other data have supported the concept that type
2 diabetes mellitus is considered a coronary heart disease* Correspondence: samuel_engel@merck.com
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reproduction in any medium, provided the orrisk equivalent; treatment guidelines for lipid management
for patients with type 2 diabetes parallel those for patients
with prior coronary events [10]. Thus, prevention of cardio-
vascular disease is a major clinical challenge in treating
patients with type 2 diabetes mellitus.
The potential role of antihyperglycaemic medications in
the development and/or progression of cardiovascular dis-
ease has received increasing attention, related in large part
to the observation that rosiglitazone was associated with an
increased incidence of cardiovascular events [11-13]. As a
reflection of the heightened concern regarding the intrinsic
effects of antihyperglycaemic agents on cardiovascular
safety, in 2008, the FDA instituted requirements for the as-
sessment of cardiovascular safety as a key component of
the clinical development programs for new antihypergly-
caemic agents [14].td. This is an Open Access article distributed under the terms of the Creative
ommons.org/licenses/by/2.0), which permits unrestricted use, distribution, and
iginal work is properly cited.
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mic therapy and improve glycaemic control by inhibiting
the inactivation of the incretin hormones, glucagon-like
peptide-1 (GLP-1) and glucose-dependent insulinotropic
polypeptide [15]. Sitagliptin, the first agent approved in
this class of antihyperglycaemic agents, was introduced
for clinical use in 2006. To date, DPP-4 inhibitors (sita-
gliptin, saxagliptin, vildagliptin, linagliptin, and aloglip-
tin) have not been shown to be associated with an
increased risk of cardiovascular events [16-20]. In view
of the increased focus on the effects of antihypergly-
caemic agents on cardiovascular outcomes, the present
analysis expanded upon a previous cardiovascular assess-
ment of sitagliptin [16] by including results from re-
cently completed sitagliptin trials.
Methods
The present post hoc analysis used a pooled population
(N = 14,611) drawn from all 25 multicenter, U.S. or multi-
national, double-blind, parallel-group studies conducted
by Merck & Co., Inc., in which patients were randomised
to receive sitagliptin 100 mg/day (n = 7,726) or a com-
parator (n = 6,885) for at least 12 weeks and up to 2 years
(the duration of the longest studies) and for which results
were available as of December 1, 2011 (complete study
listing in Appendix I, Table 2). Each protocol was reviewed
and approved by appropriate ethical review committees
and authorities for each clinical site. All patients were to
have provided written informed consent. The studies eval-
uated sitagliptin as monotherapy, initial combination ther-
apy with either metformin or pioglitazone, or add-on
combination therapy with other antihyperglycaemic agents
including metformin, pioglitazone, a sulphonylurea (with
and without metformin), insulin (with and without met-
formin), or metformin + rosiglitazone or pioglitazone.
Patients not receiving sitagliptin (i.e., the non-exposed
group) received placebo, metformin, pioglitazone, a sul-
phonylurea (with and without metformin), insulin (with
and without metformin), or metformin + rosiglitazone or
pioglitazone. From each contributing study, the pooling
was conducted by including those portions that had paral-
lel treatment groups with concurrent exposures to sita-
gliptin 100 mg/day (primarily administered as 100 mg
once daily) or other treatments (either placebo or active
comparator). Studies conducted only in Japan were
excluded from all analyses; a lower starting dose of sita-
gliptin has been separately developed in Japan. The pool-
ing excluded studies conducted in patients with moderate
to severe renal insufficiency, because these patients
received sitagliptin at doses less than 100 mg/day.
In each study, investigators were to report adverse
events (serious and non-serious) that occurred during
the conduct of the study, as well as serious adverse
events occurring within 14 days following the last doseof blinded study drug. The present analysis used patient-
level data from each study to assess the incidence rates
of cardiovascular-related adverse events that occurred
following initiation of double-blind study drug. Many
studies in this analysis included open-label glycaemic
rescue therapy, which was to have been initiated based
upon progressively stricter, protocol-specified hypergly-
caemia criteria. When initiated, glycaemic rescue therapy
was added to the ongoing, blinded study medication to
which patients had been randomised. The analysis in
this pooled population includes all post-randomisation
events reported to have occurred during a given study,
including those events with onset after the initiation of
glycaemic rescue therapy.
The primary outcome was major adverse cardiovascular
events (MACE), which comprised ischaemic events and
cardiovascular deaths (see Appendix II, Tables 3 and 4, for
the definition of MACE used in the analysis). Analyses
were performed in three cohorts: the entire 25-study
cohort (sitagliptin vs. non-exposed), the cohort from
placebo-controlled portions of studies (sitagliptin vs. pla-
cebo), and the cohort from studies comparing sitagliptin
to a sulphonylurea (sitagliptin vs. sulphonylurea). The sita-
gliptin vs. placebo analysis was performed to eliminate any
potential confounding effects from the various active
comparators. The data were pooled from the placebo-
controlled portions of 19 double-blind studies, which ran-
domised patients at baseline to sitagliptin 100 mg/day (n =
5,236) or placebo (n = 4,548) for up to 1 year (Appendix I,
Table 2). Since sulphonylureas have been associated with
an increased risk for cardiovascular events relative to met-
formin in some, but not all, observational studies [21-26],
the sitagliptin vs. sulphonylurea analysis was performed by
pooling the three double-blind studies (P010, P024, P803),
which randomised patients at baseline to sitagliptin 100
mg/day (n = 1,226) or a sulphonylurea (n = 1,225) for up
to 2 years [27-30]. Two sensitivity analyses were per-
formed to assess the robustness of the results from the
primary comparisons of sitagliptin vs. non-exposed and
sitagliptin vs. sulphonylurea. These analyses included all
trials or portions of trials in which sitagliptin 100 mg or
corresponding control were given in a blinded fashion,
even if those treatments reflected a switch from the treat-
ment given at randomization. The first sensitivity analysis
extended the primary analysis of sitagliptin vs. non-
exposed by adding all patients from two phase 2 dose-
ranging studies (P010, P014) who initially received placebo
or doses of sitagliptin less than 100 mg, but were subse-
quently switched to sitagliptin 100 mg. Only those events
that occurred after the switch to sitagliptin 100 mg were
counted in the analysis. The second sensitivity analysis
extended the primary analysis of sitagliptin vs. sulphony-
lurea by adding the same patients from P010 who were
added to the first sensitivity analysis, as well as all patients
Table 1 Baseline characteristics of randomised patients
Characteristic
Sitagliptin Non-exposed
(n = 7,726) (n = 6,885)
Age, years 54.0 ± 10.3 54.4 ± 10.5
Age ≥65 years, n (%) 1,261 (16) 1,185 (17)
Gender, n (%)
Male 4,196 (54) 3,788 (55)
Female 3,530 (46) 3,097 (45)
Race, n (%)
Caucasian 4,674 (60) 4,227 (61)
Black 427 (6) 384 (6)
Asian 1,436 (19) 1,227 (18)
Multiracial 462 (6) 427 (6)
Other or unknown 727 (9) 620 (9)
Ethnicity, Hispanic or Latino, n (%) 1,917 (25) 1,690 (25)
Body weight, kg 85.0 ± 19.6 85.8 ± 20.1
Body mass index, kg/m2 30.5 ± 5.7 30.7 ± 5.8
Duration of T2DM, years* 3.0 4.0
Distribution of duration of T2DM, n (%)†
<5 years 4,535 (59) 4,002 (58)
≥5 and <10 years 1,864 (24) 1,690 (25)
≥10 years 1,316 (17) 1,188 (17)
HbA1c, % 8.4 ± 1.3 8.4 ± 1.3
HbA1c distribution at baseline, n (%)
HbA1c <8% 3,190 (41) 2,924 (42)
HbA1c ≥8 to <9% 2,258 (29) 1,931 (28)
HbA1c ≥9% 2,264 (29) 2,016 (29)
History of CVD, n (%) 792 (10) 691 (10)
Proportion of patients with known CV
risk factors other than T2DM and history
of CVD, n (%)††
5,827 (81) 5,266 (82)
History of dyslipidaemia, n (%) 3,857 (50) 3,350 (49)
History of hypertension, n (%) 4,110 (53) 3,666 (53)
History of smoking, n (%)†† 2,712 (38) 2,539 (39)
T2DM = type 2 diabetes mellitus, CV=cardiovascular, CVD = cardiovascular
disease.
Data are expressed as mean (± standard deviation) or frequency (n [%]), unless
otherwise indicated.
* Median.
† Number of patients with unknown duration of diabetes was 11 in the
sitagliptin group and 5 in the non-exposed group.
†† Denominator is 7,177 and 6,451, respectively because history of smoking
was not routinely collected in all sitagliptin studies.
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were randomised to receive sitagliptin or placebo for the
first 24 weeks, with the placebo group switching to a sul-
phonylurea after Week 24. Only the Week 24 to Week
104 data from P020 were included in the second sensitiv-
ity analysis.
Statistical Analyses
To account for potential differences between groups in
duration of exposure to treatment, MACE was analyzed
in terms of exposure-adjusted incidence rates (i.e., the
number of patients with ≥1 event divided by the total
patient-years of exposure). For patients who had an
event, exposure was calculated as the time from the first
dose of study medication at randomisation to the time
that the first post-randomisation event occurred. For
patients without an event, exposure was calculated as
the time from the first dose to 14 days after the last
dose. Exposure-adjusted incidence rate ratios (sitagliptin
relative to comparator) and the associated 95% confi-
dence intervals (CI) were calculated using an exact
method for Poisson processes [31], stratified by study.
Studies in which no events occurred were excluded from
analyses using this approach. A sensitivity analysis was
conducted using the Mantel-Haenszel method [32],
which included studies with no events by use of a con-
tinuity correction factor. An additional sensitivity ana-
lysis was conducted using Cox regression. All analyses
were performed using SAS Version 9.1.
Results
At baseline, patients in the entire 25-study cohort (55%
male) had an average age of 54 years (range: 19 to 91
years; 17% ≥65 years), a median duration of diabetes of
3.5 years, and a mean HbA1c of 8.4% (Table 1). The co-
hort was 61% Caucasian, 18% Asian, and 6% Black. At
baseline, 10% of patients had a history of cardiovascular
disease, and 81% had additional cardiovascular risk fac-
tors besides type 2 diabetes mellitus and cardiovascular
disease, including hypertension (53%), history of dyslipi-
daemia/hypercholesterolaemia (49%), and history of
smoking (39%). There were no meaningful differences
between groups in these baseline characteristics.
The mean exposure to study drug was greater in the
sitagliptin group relative to the non-exposed group: 284
dosing days (range: 1 to 791) relative to 264 dosing days
(range: 1 to 801), respectively. In the sitagliptin group,
2,457 (32%) patients were treated for at least 1 year, with
584 of these patients treated for 2 years; the correspond-
ing numbers of patients were 1,775 (26%) and 470 in the
non-exposed group. In this pooled analysis of studies 12
weeks to 2 years in duration, the proportions of patients
discontinuing treatment were 27.2% in the sitagliptin
group and 28.8% in the non-exposed group.MACE Analyses
Entire 25-study Cohort
In the 25-study cohort, events occurred in 21 of the
studies. After excluding the 4 studies with no events
(P019, P061, P128, and P801; Appendix I, Table 2),
13,462 of the 14,611 patients contributed to the primary
analysis using the exact method, and the cumulative pa-
tient exposure was 6,157 patient-years for the sitagliptin
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group. A total of 78 patients had at least one reported
MACE-related event, with 40 in the sitagliptin group
and 38 in the non-exposed group. The exposure-
adjusted incidence rates per 100 patient-years were 0.65
in the sitagliptin group and 0.74 in the non-exposed
group (adjusted incidence rate ratio = 0.83 [95% CI:
0.53, 1.30]) (Figure 1). For cardiovascular-related deaths,
there were 12 in the sitagliptin group compared to 10 in
the non-exposed group. The exposure-adjusted inci-
dence rate for cardiovascular-related death was 0.25 per
100-patient-years for both the sitagliptin and non-
exposed group (adjusted incidence rate ratio = 0.95 [95%
CI: 0.40, 2.30]). In the sensitivity analysis that included
all blinded exposure to sitagliptin 100 mg (n = 8,128
sitagliptin, n = 6,885 non-exposed), the cumulative pa-
tient exposure excluding studies with no events was
6,596 patient-years for the sitagliptin group and 5,114
patient-years for the non-exposed group. A total of 86
patients had at least one MACE-related event reported,
with 48 in the sitagliptin group and 38 in the non-
exposed group. The exposure-adjusted incidence rate
was 0.73 per 100-patient-years in the sitagliptin group
and 0.74 in the non-exposed group (adjusted incidence

























Figure 1 Forest plot of custom MACE (Exposure-adjusted incidence ra
patients with ≥1 event/patient-years follow-up time. The estimates of rate
method stratified by study. Studies with no events in both sitagliptin and n
RR denotes adjusted incidence rate ratio.Sitagliptin vs. Placebo
Baseline characteristics were similar between treatment
arms (data not shown). The cumulative patient exposure
was approximately 3,335 patient-years with sitagliptin
and 2,922 patient-years with placebo. In this 19-study
subanalysis, 24 patients in the sitagliptin group com-
pared to 20 in the placebo group had at least one
MACE-related event. The exposure-adjusted incidence
rate was 0.80 per 100-patient-years with sitagliptin and
0.76 with placebo (adjusted incidence rate ratio = 1.01
[95% CI: 0.55, 1.86]). There were 6 cardiovascular-
related deaths in the sitagliptin group compared to 3 in
the placebo group. The exposure-adjusted incidence rate
for cardiovascular-related death was 0.28 per 100-
patient-years with sitagliptin and 0.15 with placebo (inci-
dence rate ratio = 1.79 [95% CI: 0.44, 8.79]).
Sitagliptin vs. Sulphonylurea
Baseline characteristics were similar between treatment
arms (data not shown). The cumulative patient exposure
was approximately 1,269 patient-years in the sitagliptin
group and 1,274 patient-years in the sulphonylurea group.
In this three-study subanalysis, events were reported in all
3 studies. No patients in the sitagliptin group compared to
11 in the sulphonylurea group experienced a MACE-      Sitagliptin             Non-exposed
Better            Better
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Engel et al. Cardiovascular Diabetology 2013, 12:3 Page 5 of 11
http://www.cardiab.com/content/12/1/3related event. The exposure-adjusted incidence rate was
0.00 per 100 patient-years with sitagliptin and 0.86 with
sulphonylurea (adjusted incidence rate ratio = 0.00 [95%
CI: 0.00, 0.31], reflective of no events in the sitagliptin
group). There were no cardiovascular-related deaths in
the sitagliptin group compared to 5 in the sulphonylu-
rea group. The exposure-adjusted incidence rate for
cardiovascular-related death was 0.00 per 100-patient-
years with sitagliptin and 0.39 with sulphonylurea
(adjusted incidence rate ratio = 0.00 [95% CI: 0.00, 0.81]).
In the sensitivity analysis that included all blinded expos-
ure to sitagliptin 100 mg or a sulphonylurea (n = 1,897 on
sitagliptin, n = 1,389 on a sulphonylurea), the cumulative
patient exposure was 2,044 patient-years for the sitagliptin
group and 1,486 patient-years for the sulphonylurea
group. A total of 24 patients had at least one MACE-
related event reported, with 11 in the sitagliptin group and
13 in the sulphonylurea group. The exposure-adjusted in-
cidence rate was 0.54 per 100 patient-years in the sitaglip-
tin group and 0.87 in the non-exposed group (adjusted
incidence rate ratio = 0.41 [95% CI: 0.17, 0.96]).
In sensitivity analyses for each of the cohorts evalu-
ated, nearly identical adjusted incidence rate ratios were
found for those in the MACE and death analyses using
the Mantel-Haenszel method and the adjusted hazard
ratios from Cox regression (data not shown).Discussion
In this pooled analysis of 14,611 patients from 25 clinical
studies, treatment with sitagliptin was not associated
with an increased risk of cardiovascular events relative
to the control treatments used in the studies (both active
and placebo). The present results extend and confirm
the previously reported cardiovascular safety findings
with sitagliptin [16]. To control for the confounding
effects of pooling active comparators, the present ana-
lysis also examined the effects of sitagliptin versus pla-
cebo on cardiovascular safety and found no increased
risk of cardiovascular events with sitagliptin. Further-
more, cardiovascular-related analyses with other DPP-4
inhibitors support the present findings of no evidence of
cardiovascular harm [17-20]. In these other analyses,
there also tended to be a numerical reduction in risk of
cardiovascular events with DPP-4 inhibitors relative
to non-exposure to DPP-4 inhibitors. Recently, when
Monami et al. [33] combined the results of randomised
clinical trials for DPP-4 inhibitors in a meta-analysis, a
significant reduction in risk for MACE-related events
was found with DPP-4 inhibitors. These findings need
to be confirmed in prospective studies appropriately
designed to assess cardiovascular outcomes. For sita-
gliptin, a placebo-controlled study assessing cardiovas-
cular outcomes is currently underway in patients atincreased risk for cardiovascular events (Clinicaltrials.
gov: NCT00790205; [34]).
In a subanalysis of three studies comparing treatment
with sitagliptin to sulphonylureas in patients with type 2
diabetes mellitus, a lower incidence and risk of MACE-
related events was observed with sitagliptin compared to
sulphonylurea. In the sensitivity analysis including all
blinded exposure to sitagliptin or sulphonylurea and more
reported events overall, a similar trend was observed. A
lower incidence of cardiovascular events was also reported
with linagliptin compared to glimepiride in a two-year trial
[35]. The comparison between linagliptin and glimepiride
is being further assessed in a long-term cardiovascular
outcomes trial (Clinicaltrial.gov: NCT 01243424). These
observations could reflect a deleterious effect of sulphony-
lureas, a beneficial effect of DPP-4 inhibitors, or a combin-
ation of both. While DPP-4 inhibitors and sulphonylureas
both enhance insulin secretion, there are differences in
their mechanisms of action, which have the potential for
impacting cardiovascular safety.
Sulphonylureas bind to the SUR subunit (subtype
SUR1) of the potassium ATP (KATP) channel in the beta
cell membrane and by inhibiting KATP channel activity,
increase insulin release irrespective of ambient glucose
concentrations [36]. Incretin-mediated enhancement of
insulin release, in contrast, is glucose-dependent [15]. As
a result of the mechanisms of action, hypoglycaemia is a
common side effect with sulphonylurea therapy [37],
whereas rates of hypoglycaemia with incretin-based ther-
apies are not increased relative to placebo [38]. For ex-
ample, in the three studies used for the present pooled
analysis, there was a 3- to 6-fold increase in the inci-
dence of symptomatic hypoglycaemia with sulphony-
lurea compared with sitagliptin [27-30]. Hypoglycaemia
is associated with ischaemic complications in diabetic
subjects [39]. Additionally, sulphonylureas bind to the
SUR receptor (subtype SUR2) on cardiac myocytes and
on endothelial cells, and thus may have direct effects on
cardiovascular function [40]. Sulphonylureas have also
been shown to abolish the beneficial effects of ischaemic
preconditioning, a protective mechanism whereby a brief
period of ischaemia is cardioprotective for subsequent
periods of prolonged ischaemia [41,42].
Sulphonylureas are widely used as pharmacologic ther-
apy in patients with type 2 diabetes mellitus. A concern
regarding the potential for sulphonylurea-induced car-
diovascular toxicity was first raised as a result of the
University Group Diabetes Program (UGDP) study, in
which an increase in mortality was observed with tol-
butamide compared to both insulin and to placebo [43].
While controversy ensued regarding the validity of these
findings [44,45] and their applicability to other drugs in
this class, a warning regarding the increased risk of car-
diovascular mortality was introduced and remains in the
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the United States. Long-term prospective clinical studies
have not reported an increased risk of cardiovascular
events or mortality with sulphonylurea relative to other
treatments in patients with recently- or newly-diagnosed
type 2 diabetes mellitus [46,47]. However, many, but not
all, observational studies have found an association be-
tween sulphonylurea use and an increase in cardiovascu-
lar events or mortality [21-25]. Of note, metformin was
a main comparator in these observational studies and
any differences could be attributed to the cardiovascular
benefit of metformin [48] rather than a risk related to
sulphonylurea. The combination of metformin and sul-
phonylurea has been associated with an increased risk of
death in a sub-study of UKPDS 34 [48] or the composite
endpoint of hospitalization for cardiovascular disease or
mortality in a meta-analysis of observational studies
[49]. These results have not been confirmed in a rando-
mized, prospective clinical study.
In contrast to the data suggesting a detrimental effect
of sulphonylureas on cardiovascular outcomes, preclin-
ical and clinical mechanistic studies have suggested po-
tential benefits of incretins and incretin-based therapies,
such as DPP-4 inhibitors or GLP-1 agonists, on cardio-
vascular function and outcomes [50,51]. In animals,
GLP-1 infusion protected the rat myocardium against is-
chaemia reperfusion injury [52,53]. Genetically-modified
mice that are lacking the DPP-4 enzyme had improved
survival post-myocardial infarction; similar protection
was observed in normal mice treated with sitagliptin
[54,55]. In humans, GLP-1 infusion enhanced endothe-
lial function, as measured by forearm blood flow in re-
sponse to acetylcholine; interestingly, coadministration
of the sulphonylurea glyburide, but not glimepiride,
abolished GLP-1 induced augmentation of forearm
blood flow [56]. GLP-1 infusion also improved left ven-
tricular ejection and contractile function in patients with
acute myocardial infarction [57]. In a study of patients with
coronary artery disease awaiting revascularisation, sitaglip-
tin treatment was associated with improvement in left ven-
tricular performance in response to dobutamine-induced
stress and with mitigation of post-ischaemic stunning [58].
While the potential benefits of DPP-4 inhibition have
been primarily attributed to the enhancement of GLP-1
activity, other endogenous substrates of DPP-4 could be
relevant to cardiovascular function and outcomes. Treat-
ment with sitagliptin increased plasma levels of stromal-
derived factor-1α (SDF-1α) and circulating endothelial
progenitor cells, while also reducing plasma monocyte
chemoattractant protein-1, a proinflammatory chemokine,
in patients with type 2 diabetes mellitus [59]. SDF-1α, a
chemokine, attracts stem cells to ischaemic sites and
enhances post-ischaemia angiogenesis [60]. Zaruba et al.
[61] found that, in mice in which myocardial infarctionwas induced via surgical ligation of the left ante-
rior descending artery, coadministration of granulocyte-
colony-stimulating factor (GCSF; to stimulate stem cell
mobilisation) with a DPP-4 inhibitor resulted in increased
myocardial homing of circulating CXCR-4+ stem cells,
reduced cardiac remodeling, and improved heart function
and survival. A clinical trial assessing the safety and
efficacy of sitagliptin in combination with GCSF in
patients with acute myocardial infarction is currently
underway [62].
The present results should be interpreted with caution
because of the post hoc nature of this analysis and the
clinical studies were not specifically designed to assess
cardiovascular outcomes. Additionally, the case defin-
ition used in the analysis was based on reports of ad-
verse events that matched MACE-related terms using
the Medical Dictionary for Regulatory Activities and on
cardiovascular-related deaths, rather than on the results
of a formal process of adjudication of reported events.
Any potential impact of rosiglitazone on the present
findings was likely minimal, as rosiglitazone therapy was
included in only two of the twenty-five studies. In one
study in which rosiglitazone was a comparator agent,
there were no MACE-related events reported. In the
other study that had three MACE-related events, rosigli-
tazone and metformin were background therapy in both
the sitagliptin and non-exposed groups.
The strengths of this analysis include the pooling of
data from randomized controlled trials, the use of
patient-level data, and a large sample size. The potential
influence of baseline characteristics on outcomes was
controlled by using studies in which patients were ran-
domly assigned to treatment groups. Lastly, numerous
supporting analyses confirmed the primary findings.
In summary, these analyses suggest that treatment
with sitagliptin does not increase cardiovascular risk in
patients with type 2 diabetes mellitus. In a subanalysis, a
higher rate of cardiovascular morbidity and mortality
was associated with sulphonylurea therapy relative to
sitagliptin. Whether this observation is related to a dele-
terious effect of sulphonylurea therapy, a protective ef-
fect of sitagliptin, or a combination of the two is
unknown at this time and will require future research.
Appendix I:
This analysis used a pooled population (N = 14,611)
drawn from all 25 multicenter, U.S. or multinational,
double-blind, parallel-group studies conducted by Merck
& Co., Inc., in which patients were randomised to re-
ceive sitagliptin 100 mg/day (n = 7,726) or a comparator
(n = 6,885) for at least 12 weeks and up to 2 years (the
duration of the longest studies) and for which results
were available as of December 1, 2011. Specific studies
and treatment arms are listed in Table 2.
Table 2 Studies and treatment arms included in pooled analysis
Study Study design Sitagliptin 100 mg/day group
§
(N = 7195) n
Non-exposed group
(N = 6267)§ n Reference*
P010: twice-daily dose-range finding 106-week active-controlled
period
-Sitagliptin 50 mg b.i.d. switched
to sitagliptin 100 mg q.d.
122 -Glipizide 123 [27] †
P014: once-daily dose-range finding
12-week placebo-controlled
period and 94-week active-
controlled period
-Sitagliptin 100 mg q.d. 110 -Placebo (12 weeks)
switched to metformin
(94 weeks)
111 [63] ††-Sitagliptin 50 mg b.i.d. switched
to sitagliptin 100 mg q.d.
111




-Sitagliptin 100 mg q.d. 175 -Placebo 178 [64] ††
P020: placebo-controlled add-on to
metformin study
24-week placebo-controlled
period and 80-week active-
controlled period












period and 36-week active-
controlled period









-Sitagliptin 100 mg q.d. 588 -Glipizide 584 [28,29] †
P035: placebo-controlled add-on to
glimepiride, alone or in combination
with metformin study
24-week placebo-controlled
period and 30-week active-
controlled period





P036: placebo- and active-controlled










[69-71] ††-Sitagliptin 50 mg b.i.d. +





-Sitagliptin 50 mg b.i.d. +









-Sitagliptin 100 mg q.d. 352 -Placebo 178 [72] ††
P047: placebo-controlled









-Sitagliptin 100 mg q.d. 528 -Metformin 522 [74]
P051: placebo-controlled add-on to




-Sitagliptin 100 mg q.d. 322 -Placebo 319 [75] ††
P052: placebo-controlled add-on to
metformin and rosiglitazone study
54-week placebo-controlled
period
-Sitagliptin 100 mg q.d. 170 -Placebo 92 [76] ††




-Sitagliptin 100 mg q.d. 96 -Placebo 94 [77] ††
P061: placebo- and active-controlled
mechanism of action factorial study
12-week placebo-controlled
period
-Sitagliptin 100 mg q.d. 52 -Pioglitazone 54
[78] ††-Sitagliptin 100 mg q.d. +
pioglitazone
52 -Placebo 53
P064: active-controlled study of




-Sitagliptin 100 mg q.d. +
pioglitazone
261 -Pioglitazone 259 [79,80] ††
P066: active-controlled study of




-Sitagliptin 50 mg + metformin





P068: active-controlled study of




-Sitagliptin 100 mg q.d. switched
to sitagliptin 50 mg + metformin
1000 mg b.i.d. (FDC)
244
-Pioglitazone 15 mg
q.d. titrated up to
45 mg q.d.
247 [82]




-Sitagliptin 100 mg q.d. 197 -Placebo 198 [83] ††
P079: active-controlled study of




-Sitagliptin 50 mg + metformin
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Table 2 Studies and treatment arms included in pooled analysis (Continued)
P102: active-controlled study of




-Sitagliptin 100 mg q.d. 231
[86] ††
-Sitagliptin 50 mg b.i.d. +





-Sitagliptin 50 mg b.i.d. +





-Sitagliptin 50 mg b.i.d. +





P128: placebo-controlled add-on to
metformin and pioglitazone study
26-week placebo-controlled
period
-Sitagliptin 100 mg q.d. 157 -Placebo 156 [87] ††
P801: placebo- and active-controlled
add-on to metformin study
18-week placebo-controlled
period
-Sitagliptin 100 mg q.d.
94 -Rosiglitazone 8 mg q.d. 87
[88] ††
-Placebo 91




-Sitagliptin 100 mg q.d. 516 -Glimepiride 518 [30] †
* References are for the initial phases of the studies that had extension or continuation phases, unless a reference is provided for the results beyond the initial
phase.
§ This column reflects the blinded treatment(s) to which patients were randomised. For studies identified in column 1 as "add-on" studies, all patients also
received the active therapy indicated in column 1 (open-label).
† Studies included in the primary Sitagliptin vs. Sulphonylurea comparison.
†† Studies included in the primary Sitagliptin vs. Placebo comparison. This comparison included studies where patients were randomised to sitagliptin or placebo
as monotherapy (e.g., P021) or as add-on therapy (e.g., P019), as well as studies where patients were randomised to sitagliptin + active agent or active agent
(e.g., P102). The control groups of studies in the latter category included a sitagliptin-matched placebo for purposes of blinding. For studies where the placebo
control group switched to active therapy at a post-randomisation time point (e.g., P020), only the placebo-controlled portion of the study was included.
q.d. = once daily; b.i.d. = twice daily; FDC = fixed-dose combination tablet.
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cardiovascular events (MACE)
Any adverse event with a Medical Dictionary for Regulatory
Activities (MedDRA, version 14.1) term in the following list
(Table 3) was classified as MACE. Asterisks indicate the
MedDRA terms that were reported in the present analyses.Table 3 MACE terms
Acute myocardial infarction* Haemorrhagic cerebral infarction
Basal ganglia infarction Haemorrhagic stroke*
Basilar artery thrombosis Haemorrhagic transformation stroke
Brain stem infarction* Ischaemic cerebral infarction
Brain stem stroke Ischaemic stroke*
Brain stem thrombosis Lacunar infarction*
Carotid arterial embolus Lateral medullary syndrome
Carotid artery thrombosis Moyamoya disease
Cerebellar artery thrombosis Myocardial infarction*
Cerebellar embolism Papillary muscle infarction
Cerebellar infarction* Post procedural myocardial infarction
Cerebral artery embolism Post procedural stroke
Cerebral artery thrombosis Silent myocardial infarction*
Cerebral infarction* Stroke in evolution
Cerebral thrombosis Sudden cardiac death*
Cerebrovascular accident* Thalamic infarction*
Coronary artery thrombosis Thrombotic cerebral infarction
Coronary bypass thrombosis Thrombotic stroke
Embolic cerebral infarction Wallenberg syndrome
Embolic strokeAdditionally, all deaths determined to be potentially
cardiovascular-related (based on blinded clinical review)
were classified as MACE. The reported MedDRA terms
for the MACE-related events classified as cardiovascular
(CV) deaths were as follows (Table 4):Table 4 MACE-related cardiovascular death terms
Acute myocardial infarction Fall
Cardio-respiratory arrest Haemorrhagic stroke
Cerebral ischaemia Ischaemic stroke
Coronary artery disease Myocardial infarction
Coronary artery insufficiency Myocardial ischaemia
Death Sudden cardiac death
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